{"url_path":"/sec/spro/8-k/2026-06-25/item-5-02","section_key":"item-5-02","section_title":"Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-25","source_url":"https://www.sec.gov/Archives/edgar/data/1701108/0001193125-26-283033-index.html","accession_number":"0001193125-26-283033","cik":"0001701108","ticker":"SPRO","issuer_name":"Spero Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1701108/0001193125-26-283033-index.html","primary_entity_key":"0001701108","primary_entity_name":"Spero Therapeutics, Inc."},"word_count":170,"has_tables":true,"body_markdown":"Item 5.02\n\nDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers\n\nApproval of the 2026 Stock Incentive Plan\n\nAt the 2026 Annual Meeting of Stockholders (the “Annual Meeting”) of Spero Therapeutics, Inc. (the “Company”) held on June 23, 2026, the Company’s stockholders approved the Spero Therapeutics, Inc. 2026 Stock Incentive Plan (the “2026 Plan”), which had previously been adopted by the Company’s board of directors (the “Board”), subject to stockholder approval. Subject to adjustments in accordance with the 2026 Plan, up to 12,895,866 shares of common stock may be issued from time to time pursuant to the 2026 Plan.\n\nThe description of the 2026 Plan is contained on pages 49 to 59 of the Company’s [proxy statement](http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1701108/000119312526182201/d45106ddef14a.htm#toc45106_13) for the Annual Meeting (the “Proxy Statement”), filed with the Securities and Exchange Commission (the “SEC”) on April 27, 2026, is incorporated herein by reference. A complete copy of the 2026 Plan is attached hereto as Exhibit 99.1 and is incorporated herein by reference."}